Asuragen Launches the Quantidex Pan Cancer Kit

Austin, Texas-based Asuragen has launched its Quantidex pan cancer kit, a next-generation sequencing oncology panel that classifies mutations on 21 genes associated with different cancers.

The assay, which provides analysis of both formalin-fixed paraffin embedded and fine-needle aspiration tissues, features sample multiplexing, high analytical sensitivity and the ability to profile a large number of biomarkers in a single test, the company said Wednesday.

The Cancer Prevention and Research Institute of Texas helped fund the kit’s development.

The assay is intended for research purposes only. — Jason Scott